BlackRock Capital Allocation Term Trust Vice President Stephen Thomas Minar reported exercising 7,035 transferable subscription rights for 1,407 common shares, issued on October 27, 2026. The subscription price was $13.30 per share; holders could subscribe for one new common share for every five rights, while holders of fewer than five common shares on the September 25, 2026 record date could subscribe for one share. Minar's reported direct common-stock holdings after the transaction were 8,348 shares.
BlackRock Capital Allocation Term Trust director Robert W. Fairbairn exercised 9,200 transferable subscription rights on October 27, 2026, and acquired 1,840 common shares. His reported direct common-share holdings after the transaction were 11,044 shares. The Trust’s rights offering set a subscription price of $13.30 per share and generally provided one new share for every five Rights; holders with fewer than five common shares on the September 25, 2026 record date could subscribe for one share.
BlackRock Capital Allocation Term Trust filed a post-effective amendment solely to add exhibits to its registration statement. The amendment does not modify any other part of the registration statement and became effective immediately upon filing under Rule 462(d). The trust’s annual report for the fiscal year ended December 31, 2025, including its audited financial statements and financial highlights, is incorporated by reference.
BlackRock Capital Allocation Term Trust (BCAT) is issuing 106,276,002 transferable subscription rights for 21,255,200 common shares of beneficial interest. Holders of record on September 25, 2026 receive one right per common share; five rights permit purchase of one new share, while holders with fewer than five record-date shares may subscribe for one. The estimated subscription price is $13.65 per share. The final price is based on 95% of the average sales price on the expiration date and four prior trading days, with adjustments to $0.01 below NAV if that formula price is at or above NAV, or to 98.5% of NAV if it is below 98.5% of NAV. The rights expire October 21, 2026, unless extended.
The Trust estimates net proceeds of $290,133,480.00 if all offered shares are sold; the Advisor is expected to bear approximately $517,000 in offering expenses. The Trust expects to invest proceeds within approximately three months of receipt, subject to possible delays if suitable investments are unavailable or market conditions interfere. Its full-subscription illustration estimates a 0.27% NAV-per-share reduction using $13.86 NAV and a $13.65 subscription price. New shares will not receive the October 30, 2026 distribution but are eligible for the monthly distribution expected November 30, 2026.
BlackRock Capital Allocation Term Trust (BCAT) has an initial insider ownership report on file for Francis C. Mahoney, who is identified as a director of the trust. The Form 3 shows no reportable transactions or equity holdings for him at the time of this filing.
BlackRock Capital Allocation Term Trust identifies Charles Park as its Chief Compliance Officer in an insider ownership filing. Remarks state he previously served as Chief Compliance Officer from September 24, 2020 to June 30, 2023 and was reappointed to the role effective August 1, 2026. No securities holdings or insider transactions are reported in this submission.
BlackRock Capital Allocation Term Trust portfolio manager Richard M. Rieder reported an open-market sale of 35,734 shares of Common Stock on 2026-07-13 at an average price of $15.9601 per share. Following this transaction, he directly owns 272,353 shares of the trust.
BlackRock Capital Allocation Term Trust (BCAT) and affiliated BlackRock ESG Capital Allocation Term Trust (ECAT) filed their Form N-CSR shareholder report for the fiscal period ended 12/31/2025, presenting audited financials, portfolio holdings, performance and distribution breakdowns. The filing discloses each Trust’s managed distribution plan and distribution amounts per share.
The excerpt shows BCAT’s total cumulative distributions for the fiscal period were $3.321040 per share (of which $0.338464 was net income and $2.982576 was return of capital) and ECAT’s total cumulative distributions were $3.537140 per share (including $0.219986 net income and $3.292798 return of capital). The Board-set fixed monthly amounts are $0.00 for BCAT and $0.278540 for ECAT.
BlackRock Capital Allocation Term Trust portfolio manager Sarah Croughan Thompson reported insider transactions involving common stock and phantom shares. On January 30, 2026, 693.8508 phantom shares were converted into 693.8508 common shares at an exercise price of $0.00 and then sold at $14.70 per share, leaving zero common shares directly held.
After these moves, Thompson continues to hold 1,387.7016 phantom shares, which are cash-settled instruments economically equivalent to common stock. According to the disclosure, these phantom shares were granted on January 31, 2025 and vest in three equal annual installments, becoming payable in cash as they vest.